

Metformin linked to increased risk of acute dialysis in T2DM

August 23 2016



(HealthDay)—For patients with type 2 diabetes, metformin is associated

with about a 50 percent increase in the risk of acute dialysis compared to sulfonylureas, according to a study published online Aug. 18 in *Diabetes, Obesity and Metabolism*.

Nicholas Carlson, M.D., from Copenhagen University in Denmark, and colleagues conducted a retrospective nationwide cohort study involving 168,443 drug-naïve patients with type 2 diabetes aged 50 years and older. Participants initiated treatment with [metformin](#) or sulfonylurea between 2000 and 2012 (70.7 percent initiated treatment with metformin).

The researchers found that the one-year risk for acute dialysis was 92.4 per 100,000 for sulfonylurea and 142.7 per 100,000 for metformin. The one-year risk of acute dialysis associated with metformin was increased by 50.3 per 100,000 (risk ratio, 1.53; number needed to harm, 1,988).

"In a retrospective nationwide cohort study on the risk of acute dialysis associated with initiation of metformin in patients with type 2 diabetes, treatment with metformin was associated with a 50 percent increase in risk of acute dialysis compared with sulfonylurea," the authors write.

Several authors disclosed [financial ties](#) to the [pharmaceutical industry](#).

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Metformin linked to increased risk of acute dialysis in T2DM (2016, August 23)
retrieved 9 April 2024 from
<https://medicalxpress.com/news/2016-08-metformin-linked-acute-dialysis-t2dm.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.